Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials

(2016) J. C.-H. Yang et al.   ANNALS OF ONCOLOGY

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature

(2016) A.J. van der -->Wekken et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas

(2016) Daniel B. Costa et al.   Journal of Thoracic Oncology

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

(2016) Martin Schuler et al.   Journal of Thoracic Oncology

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient

(2016) Janine Doesch et al.   LUNG CANCER

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

(2016) Shang-Gin Wu et al.   Oncotarget

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

(2015) M. Schuler et al.   ANNALS OF ONCOLOGY

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

(2015) J. Y. Lee et al.   CLINICAL CANCER RESEARCH

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma

(2015) V. Pirazzoli et al.   CLINICAL CANCER RESEARCH

Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer With T790M Mutations

(2015) Emily H. Castellanos et al.   Clinical Lung Cancer

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

(2015) Bin-Chi Liao et al.   CURRENT OPINION IN ONCOLOGY

NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:

(2015) Caroline McNeil   JNCI-Journal of the National Cancer Institute

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib

(2015) Chien-Hung Gow et al.   Journal of Thoracic Oncology

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

(2015) Bin-Chi Liao et al.   Journal of Thoracic Oncology

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

(2015) Sarayut L Geater et al.   Journal of Thoracic Oncology

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

(2015) Petra Hoffknecht et al.   Journal of Thoracic Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib

(2015) Bob T. Li et al.   LUNG CANCER

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

(2015) Lecia V. Sequist et al.   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:

(2015) Caroline McNeil   JNCI-Journal of the National Cancer Institute

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

(2014) Natasha B. Leighl et al.   JOURNAL OF CLINICAL ONCOLOGY

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis

(2014) Sanjay Popat et al.   LUNG CANCER

Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis

(2014) Chou-Han Lin et al.   LUNG CANCER

Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

(2014) M. Schuler et al.   ONCOLOGIST

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations

(2014) Y. Y. Janjigian et al.   Cancer Discovery

Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1

(2014) Valentina Pirazzoli et al.   Cell Reports

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

(2013) Mario E Lacouture et al.   Expert Review of Anticancer Therapy

Diarrhea associated with afatinib: an oral ErbB family blocker

(2013) James Chih-Hsin Yang et al.   Expert Review of Anticancer Therapy

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

(2013) Nobuyuki Katakami et al.   JOURNAL OF CLINICAL ONCOLOGY

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations

(2013) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

(2012) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

(2009) Lucia Regales et al.   JOURNAL OF CLINICAL INVESTIGATION